Skip to main content

Advertisement

SpringerLink
Log in

Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To assess the levels of receptor activator of NF-κB ligand (RANKL) in serum and synovial fluid (SF) of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to correlate its levels with disease activity and severity. Serum and SF levels of RANKL were measured in 24 patients with RA (Group I) and 20 patients with OA (Group II); patients were selected according to the ACR criteria, and serum RANKL was measured in 13 healthy controls. All patients were subjected to full rheumatological assessment. In RA group, serum level of RANKL was significantly higher than control group (P = 0.01), but not correlated with disease activity and severity parameters apart from number of tender joints (P = 0.03). SF level of RANKL was significantly correlated with disease duration (P = 0.02), number of tender (P = 0.002) and swollen joints (P = 003), ESR (P = 0.01), CRP (P = 0.000), DAS-28 (P = 0.004), and SENS (P = 0.03). In patients with OA, serum level of RANKL was significantly higher than the control group (P < 0.001), and it was statistically insignificant with clinical, laboratory, or radiological data, while SF level of RANKL was statistically significantly higher in patients with Heberden and Bouchard nodes (P = 0.007), Kellgren—Lawrence score (P = 0.002), and with the erosive changes of hands (P = 0.006). The mean serum RANKL in RA group was insignificant with that of total OA group. SF level of RANKL was significantly higher in RA than erosive OA patients and in erosive than non-erosive OA with (P = 0.001, in each one). The SF level of RANKL is an important marker of both disease activity and severity in RA patients; while in OA patients, it is an important marker of disease severity especially in erosive than non-erosive types. Serum level of RANKL may be of low benefit in disease activity and severity of both rheumatoid arthritis and osteoarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rojkovich B, Poor G (2002) Prognostic factors in rheumatoid arthritis. Orv Hetil 143(35):2019–2026

    Google Scholar 

  2. Harris ED (1990) Rheumatoid arthritis; Pathophysiology and implications for therapy. N Engl J Med 322:1277–1289

    Article  PubMed  Google Scholar 

  3. Sambrook PN, Eisman JA, Champion GD, Pocock NA, Eberl S, Yeates MG (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721–728

    Article  PubMed  CAS  Google Scholar 

  4. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalized bone loss in patients with early rheumatoid arthritis occurs early and relates to disease activity. Lancet 344:23–27

    Article  PubMed  CAS  Google Scholar 

  5. Gravallese EM, Manning C, Tsay A et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258

    Article  PubMed  CAS  Google Scholar 

  6. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003–1012

    Article  PubMed  CAS  Google Scholar 

  7. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NF kappa B ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30:340–346

    Article  PubMed  CAS  Google Scholar 

  8. Lawerence RC, Helmock CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculskeletal disorders in the United States. Arthritis Rheum 41:778–799

    Article  Google Scholar 

  9. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegrin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176

    Article  PubMed  CAS  Google Scholar 

  10. David RH (2007) Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis Res & Therapy 9:104

    Article  Google Scholar 

  11. Arnett FC, Edworthy SM, Bloch DA et al (1987) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  Google Scholar 

  12. Altman R, Asch E, Bloch D et al (1986) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 29:1039–1049

    Article  PubMed  CAS  Google Scholar 

  13. Ritchie DM, Boyle JA, Mclnnes JM et al (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393–406

    PubMed  CAS  Google Scholar 

  14. Ferraz MB, Quaresma MR, Aquino LR et al (1990) Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 17(8):1022–1024

    PubMed  CAS  Google Scholar 

  15. Fries JF, Spitz P, Kraines G et al (1980) Measurement of patient outcome in Arthritis. Arthritis Rheum 23:137–145

    Article  PubMed  CAS  Google Scholar 

  16. Prevoo MLL, van’t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 38:44–48

    Article  PubMed  CAS  Google Scholar 

  17. Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840

    PubMed  CAS  Google Scholar 

  18. Trofimov S, Pantsulaia I, Tobyliansky E et al (2004) Circulating levels of receptor activator of NF kappa B ligand-osteoprotegrin-macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 11:150–305

    Google Scholar 

  19. Van der Heijde D (1999) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26:743–745

    PubMed  Google Scholar 

  20. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494–502

    Article  PubMed  CAS  Google Scholar 

  21. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesis inhibitory factor (OCIF) and is identical to TRANCE/RANKL. Pro Natl acad Sci USA 95:3597–3602

    Article  CAS  Google Scholar 

  22. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323

    Article  PubMed  CAS  Google Scholar 

  23. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319

    Article  PubMed  CAS  Google Scholar 

  24. Kong Y-Y, Feige U, Sarosi I et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309

    Article  PubMed  CAS  Google Scholar 

  25. Minenna G, D’Amore S, Maggiolini P, Scagliusi P, D’Amore M (2005) RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report Recenti Prog Med 96(9):431–432

    Google Scholar 

  26. Crotti TN, Smith MD, Weedon H et al (2002) Receptor activator NF-kappa B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047–1054

    Article  PubMed  CAS  Google Scholar 

  27. Skoumal M, Kolarz G, Haberhauer G et al. (2005) Osteoprotegerine and the receptor activator of NF-Kappa B ligand in serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26(1): 63–69. (Epub May 12)

    Google Scholar 

  28. Krystufkova1 O, Niederlova1 J, Senolt1 V et al. (2003) OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis, osteoarthritis and spondylarthropathy. Arthritis Res Ther 5(Suppl 1):102

    Google Scholar 

  29. Haynes DR, Crotti TN, Loric M et al (2001) Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623–630

    Article  PubMed  CAS  Google Scholar 

  30. Komuro H, Olee T, Kühn K et al (2001) The osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 44(12):2768–2776

    Article  PubMed  CAS  Google Scholar 

  31. Bekker PJ, Holloway D, Nakanishi A et al (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348–360

    Article  PubMed  CAS  Google Scholar 

  32. Georg S (2007) Erosive Arthritis. Arthritis Res Ther. 9 (Supp), BioMed Central, Ltd

Download references

Conflict of interest

Not present among all the authors.

 

Ethical Committee Approval was done before start of the research work.

Author information

Authors and Affiliations

  1. Departments of Rheumatology and Rehabilitation, Faculty of medicine, Minia University, El-Minia, 61111, Egypt

    Abdou S. Ellabban, Shereen Refaat Kamel & Shimaa S. Ahmed

  2. Clinical Pathology, Minia University, El-Minia, Egypt

    Ashraf M. Osman

Authors
  1. Abdou S. Ellabban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shereen Refaat Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shimaa S. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ashraf M. Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdou S. Ellabban.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellabban, A.S., Kamel, S.R., Ahmed, S.S. et al. Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int 32, 1589–1596 (2012). https://doi.org/10.1007/s00296-011-1831-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1831-0

Keywords

Search

Navigation